| Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161 JM Mjösberg, S Trifari, NK Crellin, CP Peters, CM van Drunen, B Piet, ... Nature Immunology 12 (11), 1055-1062, 2011 | 1320 | 2011 |
| Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells P Hombrink, C Helbig, RA Backer, B Piet, AE Oja, R Stark, G Brasser, ... Nature immunology 17 (12), 1467-1478, 2016 | 420 | 2016 |
| CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung B Piet, GJ de Bree, BS Smids-Dierdorp, CM van der Loos, ... The Journal of clinical investigation 121 (6), 2254-2263, 2011 | 202 | 2011 |
| Trigger-happy resident memory CD4+ T cells inhabit the human lungs AE Oja, B Piet, C Helbig, R Stark, D Van Der Zwan, H Blaauwgeers, ... Mucosal immunology 11 (3), 654-667, 2018 | 151 | 2018 |
| Functional Heterogeneity of CD4+ Tumor-Infiltrating Lymphocytes With a Resident Memory Phenotype in NSCLC AE Oja, B Piet, D Van der Zwan, H Blaauwgeers, M Mensink, S De Kivit, ... Frontiers in Immunology 9, 2654, 2018 | 111 | 2018 |
| Multicenter comparison of molecular tumor boards in the Netherlands: definition, composition, methods, and targeted therapy recommendations B Koopman, HJM Groen, MJL Ligtenberg, K Grünberg, K Monkhorst, ... The Oncologist 26 (8), e1347-e1358, 2021 | 42 | 2021 |
| Programmed cell death-1/ligand-1 PET imaging: a novel tool to optimize immunotherapy? SR Verhoeff, MM van den Heuvel, CML van Herpen, B Piet, ... PET clinics 15 (1), 35-43, 2020 | 39 | 2020 |
| Analysis of stem-cell-like properties of human CD161++ IL-18Ra+ memory CD8+ T cells SHC Havenith, S La Yong, SM Henson, B Piet, MM Idu, SD Koch, ... International Immunology, 2012 | 37 | 2012 |
| A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies JI Scott, L Mendive-Tapia, D Gordon, ND Barth, EJ Thompson, Z Cheng, ... Nature communications 13 (1), 2366, 2022 | 29 | 2022 |
| Mechanisms of immune checkpoint inhibitor-mediated colitis H Westdorp, MWD Sweep, MAJ Gorris, F Hoentjen, MJ Boers-Sonderen, ... Frontiers in Immunology 12, 768957, 2021 | 29 | 2021 |
| Recent advances and future perspective of DC-based therapy in NSCLC IAE van der Hoorn, G Flórez-Grau, MM van den Heuvel, IJM de Vries, ... Frontiers in Immunology 12, 704776, 2021 | 13 | 2021 |
| Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination LL van der Woude, MAJ Gorris, IMN Wortel, JHA Creemers, K Verrijp, ... Journal for ImmunoTherapy of Cancer 10 (10), 2022 | 11 | 2022 |
| Mechanisms, management and prevention of pemetrexed-related toxicity N de Rouw, B Piet, HJ Derijks, MM van den Heuvel, R Ter Heine Drug safety 44 (12), 1271-1281, 2021 | 11 | 2021 |
| Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer LS Otten, B Piet, MM van den Heuvel, C Marzolini, RMJM van Geel, ... European Respiratory Review 31 (164), 2022 | 8 | 2022 |
| SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer H Borghaei, F de Marinis, D Dumoulin, C Reynolds, W Theelen, ... Annals of Oncology 35 (1), 66-76, 2024 | 6 | 2024 |
| Erratum: Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells P Hombrink, C Helbig, RA Backer, B Piet, AE Oja, R Stark, G Brasser, ... Nature immunology 18 (2), 246-246, 2017 | 5 | 2017 |
| Imaging the rewired metabolism in lung cancer in relation to immune therapy EAJ van Genugten, JAM Weijers, S Heskamp, M Kneilling, ... Frontiers in Oncology 11, 786089, 2022 | 4 | 2022 |
| Evidence‐based rationale for low dose nivolumab in critically ill patients with sepsis‐induced immunosuppression DAC van den Haak, LS Otten, HJPM Koenen, RL Smeets, B Piet, ... Clinical and Translational Science 16 (6), 978-986, 2023 | 3 | 2023 |
| Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients SE Koele, SW van Beek, AJ van der Wekken, B Piet, MM van den Heuvel, ... British journal of clinical pharmacology 88 (4), 1930-1934, 2022 | 3 | 2022 |
| Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry IAE van der Hoorn, E Martynova, B Subtil, J Meek, K Verrijp, J Textor, ... European Journal of Immunology 54 (1), 2350616, 2024 | 2 | 2024 |
